Amplification of the MYCN oncogene predicts treatment resistance in childhood neuroblastoma. We used a MYC target gene signature that predicts poor neuroblastoma prognosis to identify the histone chaperone FACT (facilitates chromatin transcription) as a crucial mediator of the MYC signal and a therapeutic target in the disease. FACT and MYCN expression created a forward feedback loop in neuroblastoma cells that was essential for maintaining mutual high expression. FACT inhibition by the small-molecule curaxin compound CBL0137 markedly reduced tumor initiation and progression in vivo. CBL0137 exhibited strong synergy with standard chemotherapy by blocking repair of DNA damage caused by genotoxic drugs, thus creating a synthetic lethal environment in MYCN-amplified neuroblastoma cells and suggesting a treatment strategy for MYCN-driven neuroblastoma.
INTRODUCTION
Neuroblastoma is a pediatric cancer of the sympathetic nervous system, which often presents at a clinically advanced stage with primary or acquired resistance to conventional chemotherapy (1, 2) . Amplification of the c-MYC homolog MYCN is observed in~15 to 20% of patients (3, 4) , and this feature strongly correlates with poor clinical outcome (1, 2) . Direct evidence of MYCN as an oncogene is highlighted by the TH-MYCN mouse model, in which a MYCN transgene driven by the tyrosine hydroxylase (TH) promoter is sufficient to recapitulate many of the features of human neuroblastoma (5) . In addition to MYCN amplification being an effective biomarker for poor prognosis in high-risk neuroblastoma patients, it has also been reported that increased activation of MYC transcriptional target genes predicts poor prognosis in clinical stage 4 patients, independently of MYCN amplification (6) . Paradoxically, these patients had very low expression of MYCN, suggesting that c-MYC, the expression of which is inversely correlated to MYCN, acts in a functionally redundant manner for MYC-directed transcription (6) . Thus, targeting genes downstream of MYC proteins may be an alternative therapeutic strategy for high-risk neuroblastoma patients.
Here, we used a prognostic MYC target gene signature to identify the histone chaperone FACT (facilitates chromatin transcription) as a promising therapeutic target in neuroblastoma. We found that FACT and MYCN expression act in a positive feedback regulatory loop in neuroblastoma cells, are strongly correlated during tumor initiation, and result in a remarkable susceptibility of neuroblastoma cells to the FACT inhibitor CBL0137. Moreover, because of the role of FACT in DNA repair, CBL0137 created a synthetic lethal environment when combined with genotoxic chemotherapy, suggesting a promising treatment approach for this aggressive childhood malignancy.
RESULTS
A MYC target gene signature identifies the histone chaperone FACT as a prognostic marker in neuroblastoma To identify MYC target genes as therapeutic targets in neuroblastoma, we examined the expression of a previously reported MYC core target gene signature (7) in neuroblastoma tumors derived from patients at primary diagnosis. We conducted an unsupervised hierarchical clustering on 649 neuroblastoma patients (4) , and as expected, this identified not only marked up-regulation in a cluster that corresponded to MYCN-amplified tumors (MYCN-amplified cluster) but also high expression in some MYCN-nonamplified tumors (MYC activation cluster) (Fig. 1A) . The MYC activation cluster was associated with indicators of poor prognosis, including older patient age (>18 months) or FACT predicts poor prognosis in neuroblastoma patients and is associated with MYC signaling. (A) Unsupervised hierarchical clustering on 649 neuroblastoma patients according to a 51-gene MYC target signature (7) . Clinical parameters (top) were included as follows: patient age (>18 months: red; <18 months: green), MYCN amplification status (amplified: red; nonamplified: green), and International Neuroblastoma Staging System (stage 1 + 2: green; stage 3: orange; stage 4: red; stage 4S: blue). Clustering was performed according to the Euclidean distance using the R2 microarray analysis and visualization platform (http://r2.amc.nl). (B) Kaplan-Meier plots for overall survival of 649 neuroblastoma patients stratified by expression quartiles of the MYC target signature. MYC target signature expression quartiles were generated by averaging the expression of all 51 gene members of the MYC signature per patient and ranking from lowest to highest: Q1, 0 to 25th patient percentile; Q2, 25th to 50th patient percentile; Q3, 50th to 75th patient percentile; and Q4, 75th to 100th patient percentile. P value, pairwise log-rank tests on Q1 versus Q4, Q2 versus Q4, or Q3 versus Q4. See table S7 for individual P values. (C) Kaplan-Meier plots for overall survival of 649 neuroblastoma patients stratified by expression quartiles of SPT16 (left) and SSRP1 (right) as for (B) above. advanced clinical stage 3 or 4, and the MYC target signature as a whole strongly predicted poor overall and event-free survival (Fig. 1, A (table  S1) . Eleven of 51 genes were found to be significant predictors of poor prognosis in all three analyses (table S1). Among these 11 candidates, we sought a MYC-regulated target with a clinically relevant and strong chemical inhibitor and preclinical/clinical evidence for a role in cancer (table S2) . Suppressor of Ty 16 (SUPT16H; hereafter referred to as SPT16) was the only gene that conformed to these criteria. Together with structure-specific recognition protein 1 (SSRP1), SPT16 comprises the histone chaperone heterodimer complex FACT (8, 9) , which has been identified as a potential therapeutic target in a number of cancer models (10) (11) (12) . Curaxin class compounds, including the lead compound CBL0137, are potent inhibitors of FACT that deplete free FACT from the soluble fraction of the nucleus, functionally reducing FACT regulation of chromatin (12) . CBL0137 exhibits potent antitumor efficacy and minimal toxicity in experimental cancer models (12) and is currently being tested in early-phase clinical trials (http:// clinicaltrials.gov/show/NCT01905228).
SPT16 and SSRP1 are highly dependent on each other for regulation of expression and function (13), so we next examined the expression of SSRP1 and SPT16 in neuroblastoma tumors. Both FACT subunits were associated with poor overall and event-free survival in two cohorts of primary neuroblastoma patients (Fig. 1C  and fig. S1 , B and C) (4, 14) . Using Cox proportional hazards modeling, we found high mRNA expression of SSRP1 and SPT16 to be strong and independent predictors of poor prognosis by univariate analysis or when considering MYCN amplification status alone or combined with patient age and stage ( fig. S1 , N to Q).
FACT and MYCN expression are controlled in a forward feedback loop Because SPT16 is a direct transcriptional target of c-MYC in fibrosarcoma cell lines (7), we hypothesized that MYCN transcriptionally regulates FACT expression in neuroblastoma cells. Consistent with this prediction, small interfering RNA (siRNA) knockdown of MYCN decreased SPT16 and SSRP1 mRNA and protein expression in MYCNamplified BE(2)C and KELLY neuroblastoma cell lines (Fig. 2, A and  B) . Both SPT16 and SSRP1 gene promoters contain a MYC E-box transactivation motif~500 base pairs upstream of their transcriptional start sites. We used chromatin immunoprecipitation assays to demonstrate enrichment of MYCN at the E-box motif of both the SPT16 and SSRP1 Data displayed were obtained 48 hours after transfection and were normalized to mRNA expression in a control siRNA sample. b2-Microglobulin (b2M) was used as a reference gene. *P < 0.05, **P < 0.01, ***P < 0.001. See S2D ).
FACT regulates nucleosome structure to promote transcriptional initiation and elongation (8, 9) . Because FACT is enriched at the c-MYC promoter in HT1080 fibrocarcinoma cells (10), we hypothesized that FACT may also enhance the transcription of MYCN in neuroblastoma cells, completing a forward feedback loop. Indeed, we found that siRNA knockdown of SSRP1 and SPT16 decreased MYCN mRNA and protein expression ( FACT is highly expressed in neuroblastoma precursor cells in TH-MYCN +/+ mice We have previously shown that high MYCN expression caused postnatal persistence and hyperplasia of neuroblasts as precancerous lesions in the developing sympathetic ganglia of TH-MYCN mice (15) . Immunohistochemical analyses showed that in wild-type ganglia, SSRP1 protein expression was rapidly down-regulated after birth, whereas TH-MYCN +/+ ganglia displayed high SSRP1 expression up until tumor formation at 6 weeks of age ( Fig. 3A and fig. S3A ). SSRP1 expression was highly correlated with MYCN expression (Fig. 3A and  fig. S3 , A to C), and the degree of MYCN and SSRP1 expression was highly correlated with the extent of neuroblast hyperplasia in ganglia ( Fig. 3B and fig. S3 , A and D to F). These results suggest that FACT is up-regulated in precancerous TH-MYCN +/+ neuroblasts.
FACT inhibitor CBL0137 restores developmental signals in postnatally persistent neuroblasts from TH-MYCN mice
To evaluate whether FACT is required for TH-MYCN neuroblast persistence and hyperplasia, we treated perinatal TH-MYCN mice with the FACT inhibitor CBL0137. Low-dose intraperitoneal administration of CBL0137 from 6 days of age for a total of 5 days reduced the proportion of ganglia with neuroblast hyperplasia in both hemizygote (TH-MYCN +/− ) and homozygote (TH-MYCN +/+ ) mice at 2 weeks of age (Fig. 3 , C and D). Furthermore, low-dose CBL0137 prophylaxis from 6 days of age until 4 weeks of age delayed subsequent tumor growth in TH-MYCN +/+ mice (Fig. 3E ). Histological analysis of tumors from mice given CBL0137 prophylaxis revealed an increase in ganglion-like cells within tumors ( fig. S3G ), suggesting that CBL0137 promoted the differentiation of neuroblasts that had pathologically persisted postnatally. Consistent with this observation, we also demonstrated that all-trans retinoic acid treatment of the human neuroblastoma cell line SH-SY5Y rapidly down-regulated expression of both SSRP1 and SPT16 ( fig. S3H ) at a time that coincided with terminal neuritic differentiation in vitro (16, 17) .
We have previously shown that MYCN blocked developmental cell deletion signals in premalignant TH-MYCN +/+ ganglia cells after nerve growth factor or serum withdrawal in vitro, which mirrored postnatal neuroblast persistence and hyperplasia in vivo (15, 18, 19) . To evaluate the role of FACT in neuroblast death responses, we cultured primary ganglia from 2-week-old TH-MYCN +/+ mice with CBL0137. TH-MYCN +/+ ganglia were more sensitive to the cytopathic effects of CBL0137 in cultures deprived of serum compared with wild-type ganglia ( Fig. 3F  and fig. S3I ). Moreover, when 1-week-old TH-MYCN +/+ mice were treated with low-dose CBL0137 for 5 days, primary ganglia cultures derived from treated mice also exhibited sensitivity to trophic factor withdrawal compared with vehicle-treated mice ( fig. S3J ). Together, this suggested that CBL0137 restored normal cell deletion responses to trophic factor withdrawal, despite high MYCN expression, blocking the earliest steps of this MYCN-driven embryonal cancer.
We have previously shown that p53 stress responses to trophic factor withdrawal are impaired in a MYCN-dependent manner in TH-MYCN +/+ ganglia compared with wild-type ganglia (19) . Consistent with this observation, gene set enrichment analysis identified suppression of gene sets related to p53 target genes in TH-MYCN +/+ mice compared with age-matched wild-type mice (table S4) . CBL0137 has previously been shown to activate p53; thus, we evaluated whether CBL0137 could restore p53 stress responses in serum-deprived TH-MYCN +/+ ganglia. Rescue experiments with the p53 inhibitor pifithrin-a (PFTa) (20) and the pan-caspase inhibitor OPH-Q-VD demonstrated that CBL0137 sensitized TH-MYCN +/+ ganglia to trophic factor withdrawal in a p53-dependent manner ( fig. S3K ) and required activation of caspase signaling ( fig. S3L ). Inactivation of p53 as the mechanism of resistance to trophic withdrawal in TH-MYCN +/+ ganglia was further supported by the finding that the p53 signal activator Nutlin-3a (21) also restored the death responses to trophic factor withdrawal in a p53-dependent, proapoptotic manner (fig. S3, M to P).
FACT inhibition is an effective therapeutic strategy for MYCN-driven neuroblastoma Next, we examined the impact of FACT inhibition on neuroblastoma cell viability. FACT siRNAs reduced cell viability of BE (2) S4, C and D) . CBL0137 was highly toxic to a panel of seven human neuroblastoma cell lines compared with normal fibroblasts and was particularly potent against neuroblastoma cell lines with high c-MYC or MYCN protein expression (Fig. 4A and figs. S1N and S4E ). Consistent with this observation, CBL0137 markedly decreased colony-forming capacity of doxycyclinetreated SHEP.MYCN3 cells, as well as MYCN mRNA, MYCN protein, and MYCN binding to the promoter of FACT subunits in BE(2)C and KELLY cells (Fig. 4, B to D, and fig. S4F ).
We have previously shown that CBL0137 exhibited promising antitumor efficacy in multiple preclinical cancer models (12) , so we next examined CBL0137 in vivo against established neuroblastoma in TH-MYCN +/+ mice. Intravenous administration of CBL0137 (60 mg/kg; every 4 days for eight doses) to 6-week-old TH-MYCN +/+ mice with advanced neuroblastoma delayed tumor growth, with most mice exhibiting long-term tumor regression (Fig. 5A and fig. S5A ). Oral CBL0137 (20 mg/kg; five doses weekly for 4 weeks) and low-dose intravenous CBL0137 (40 mg/kg; every 4 days for eight doses) were less effective but still prolonged time until maximum tumor burden (Fig. 5A and fig. S5A ). We next examined the histology of tumors derived from TH-MYCN +/+ mice after short-term CBL0137 treatment as either an oral (20 mg/kg for 5 days) or an intravenous (20, 40, or 60 mg/kg for 1 day) formulation. We found that the tumor tissue demonstrated a marked treatment effect, particularly for the intravenously treated (60 mg/kg) group, characterized by extensive necrosis, hemorrhage, and apoptosis compared to controls (Fig. 5B, fig. S5B , and tables S5 and S6). Moreover, intravenous CBL0137 (60 mg/kg)-treated mice exhibited evidence of metastatic regression with no mice demonstrating pulmonary metastases, whereas vehicle-and low-dose CBL0137-treated mice demonstrated marked metastatic spread to the lungs ( fig. S5C ). There was a substantial accumulation of CBL0137 in treated tumors compared to other organs/body fluids, with intravenous CBL0137 (60 mg/kg)-treated animals showing the highest concentrations of intratumoral CBL0137 ( fig. S5D ). Tumor concentrations of CBL0137 also showed a strong inverse correlation with tumor viability (Fig. 5C  and fig. S5E ). SSRP1, SPT16, and MYCN protein expression was decreased in intravenous CBL0137 (60 mg/kg)-treated tumors compared to both oral CBL0137 and vehicle treatment (Fig. 5D) . Moreover, intravenous administration of CBL0137 to BALB/c nude mice bearing flank xenografts of the human neuroblastoma cell line BE(2)C resulted in delayed tumor growth and decreased MYCN protein expression ( fig. S5, F and G) . Together, this suggests that the inhibitory effect of CBL0137 on FACT has a downstream negative impact on MYCN expression and results in a marked therapeutic selectivity for MYCNdriven neuroblastoma tissues in vitro and in vivo.
CBL0137 exhibits synergy with DNA-damaging cytotoxic chemotherapy Knockdown of SSRP1 has been previously identified to sensitize ovarian and breast cancer cells to cytotoxic chemotherapy (22) , suggesting that CBL0137 may enhance neuroblastoma chemotherapy. We used colony formation and cell viability assays in neuroblastoma cells to demonstrate that CBL0137 synergizes with mafosfamide (the active metabolite of cyclophosphamide) and that this synergy was exclusive to neuroblastoma cells in comparison with normal primary fibroblasts ( Fig. 6A and fig. S6A ). The combination of CBL0137 and mafosfamide was far more toxic in neuroblastoma cells compared to normal controls, indicating that a wide therapeutic index exists for this combination treatment ( fig. S6B ). CBL0137 combination synergy extended to several other chemotherapeutics used in neuroblastoma therapy, albeit with some exceptions (fig. S6, C and D) . Consistent with these findings, cyclophosphamide, etoposide, cisplatin, and vincristine each potently increased CBL0137 efficacy in vivo against established TH-MYCN +/+ tumors (Fig. 6B) . Moreover, when intravenous CBL0137 was combined with clinically relevant chemotherapy regimens used to treat high-risk/refractory neuroblastoma patients, namely, cyclophosphamide/topotecan and irinotecan/temozolomide, strong tumor delay was observed in both the TH-MYCN +/+ transgenic mice (Fig. 6C) and BALB/c nude mice harboring BE(2)C xenografts ( fig. S6E ). Combination therapies were mostly well tolerated in recipient mice, with CBL0137/vincristine a notable exception. Some occasions of weight loss were observed, and mice were removed from the study as follows: cisplatin (2 of 10 mice), cisplatin/CBL0137 (2 of 10 mice), vincristine/CBL0137 (5 of 10 mice), and CBL0137/irinotecan/ temozolomide (2 of 10 mice). FACT was previously implicated in cisplatin resistance as part of a DNA repair complex containing DNA-PK (DNA-dependent protein kinase) (22) , and it is well established to have roles in DNA repair (8, 23, 24) . Thus, we reasoned that the synergy exhibited by CBL0137 in combination with genotoxic chemotherapy may be dependent on inhibiting FACT during DNA repair. Thus, we next examined the extent of DNA repair when CBL0137 was added to cells after they were treated with the genotoxic agents cisplatin or etoposide. CBL0137 inhibited DNA double-strand break repair, which otherwise occurred after withdrawal of either cisplatin or etoposide, even though CBL0137 exhibited no genotoxicity alone (Fig. 7A) . Moreover, CBL0137 resulted in a marked increase in DNA damage markers gH2AX and 53BP1 in the presence of etoposide (Fig. 7, B and C). These findings were recapitulated when inhibition of DNA repair by CBL0137 was evaluated after hydroxyurea treatment, but not when CBL0137 was added after vincristine ( fig. S7, A and B) , suggesting that the synergistic action of CBL0137 was specific to direct DNA-damaging agents and not microtubule poisons.
DISCUSSION
Pathologic epigenetic regulation of transcription by abnormal chemical modification of histone tails and DNA methylation has been extensively studied in human cancer (25) . However, less is known about the role of nucleosome remodelers, such as the histone chaperone proteins in cancer (26) . Here, we used a MYC target gene expression signature to identify the H2A/H2B histone chaperone FACT as a key driver and treatment target in the MYCN-driven pediatric cancer neuroblastoma. FACT and MYCN expression acted in a forward feedback loop, and chemical inhibition of FACT impaired neuroblastoma initiation, suggesting that FACT and MYCN may together inhibit developmentally timed maturation signals in TH-MYCN +/+ mice. This oncogenic cooperation between MYCN and FACT created a synthetic lethality when conventional DNA-damaging chemotherapy was administered with the FACT inhibitor CBL0137, providing the mechanistic basis for a combination anticancer therapy approach.
Aberrant activity of nucleosome remodeling proteins has been observed in pediatric cancer. Most evidence suggests that these proteins more frequently act as tumor suppressors, as evidenced by the loss-of-function mutations in SWI/SNF complexes in malignant rhabdoid tumors (27) and genomic alterations of the H3.3 chaperone ATRX in neuroblastoma (14) and pediatric glioma (28) . In contrast, our data support a gain-of-function model whereby FACT is present in pathologically high amounts in cancer tissues. Although there are other examples of similar "oncogenic" histone chaperones such as DEK (29) and CHAF1A (30) , this study identifies an oncogenic histone chaperone that has a potent and effective chemical inhibitor available for clinical use.
FACT is normally expressed in embryonal or primitive tissues and is thereafter down-regulated during tissue differentiation and in mature tissues, in a manner similar to MYCN (11, 13, 31) . We showed a strong correlation between MYCN and FACT expression in normal sympathetic ganglia, including high expression in normal developmental neuroblasts, the putative cell of origin of neuroblastoma (15, 18) . SSRP1 knockout mice are embryonic lethal before E5.5 (32), so later developmental roles are unknown, but this expression pattern suggests that FACT may function in physiological regulation of sympathoadrenal development. Our data show that FACT expression is also correlated with MYCN at tumor initiation, and chemical inhibition of FACT delayed neuroblastoma onset. This suggests that FACT may have functions in neuroblastoma tumor initiation and progression. This is consistent with the observation that aberrant expression or activity of developmental Colony-forming assays were performed for BE(2)C and KELLY cells treated with CBL0137 (CBL) in combination with mafosfamide (MAF), the active metabolite of cyclophosphamide. Combination index (CI) at a fractional cell kill of 0.80 is shown using the Chou-Talalay method (43) . CI <0.9, synergistic. Data are displayed as the average number of colonies at each concentration of drugs from three independent biological replicates ± SE. (B) Kaplan-Meier plots of tumor-bearing TH-MYCN +/+ mice treated with vehicle (5% dextrose) or intravenous CBL0137 (40 mg/kg; once every 4 days for 4 weeks) combined with cyclophosphamide (CPM; 15 mg/kg per day), etoposide (VP16; 6 mg/kg per day), cisplatin (2 mg/kg per day), or vincristine (VCR; 2 mg/kg per day). Mice were treated starting at 6 weeks of age, when 5-mm palpable tumors were detected. Endpoint was at 10-mm tumor diameter by palpation. Cyclophosphamide, etoposide, cisplatin, and vincristine were all administered intraperitoneally for five consecutive days when treatment began. P value was determined using pairwise log-rank test for CBL0137/chemotherapy combinations versus their respective single treatment controls. ℞ indicates treatment period. (C) KaplanMeier plots of tumor-bearing TH-MYCN +/+ mice treated with vehicle (5% dextrose) or intravenous CBL0137 (40 mg/kg; once every 4 days for 4 weeks) combined with cyclophosphamide (10 mg/kg per day) and topotecan (TOPO; 5 mg/kg per day) (left) or irinotecan (IRINO; 2 mg/kg per day) and temozolomide (TEMOZ; 5 mg/kg per day) (right). Mice were treated at 6 weeks of age, starting when 5-mm palpable tumors were detected. Endpoint was at 10-mm tumor diameter by palpation. Cyclophosphamide, topotecan, irinotecan, and temozolomide were all administered intraperitoneally for five consecutive days when treatment began. P value was determined using pairwise log-rank test for CBL0137/chemotherapy combinations versus their respective treatment controls. ℞ indicates treatment period.
regulators are key determinants of neuroblastoma tumorigenesis (18) . Animal models with conditional knockout of SSRP1 or SPT16 will reveal more specific roles of FACT in sympathoadrenal development and, by association, in MYCN-driven tumorigenesis.
FACT controls nucleosome "eviction" and "reassembly" of histones, thus promoting the smooth passage of RNA polymerase II during gene transcription (8, 9, 33) . Our previous data have demonstrated that SSRP1 is enriched at the promoter regions of oncogene transcription factors and their respective transcriptional targets (10) . We show here that FACT maintains high concentrations of MYCN protein in neuroblastoma cells by driving MYCN transcription and protein stability. Moreover, FACT is a functional cofactor to oncogenic mutant H-Ras V12 in malignant transformation of mammary epithelial cells (10) . These observations support a model whereby FACT drives both malignant transcription and oncogenic transcription factor activity, yet the mechanism that governs FACT transcriptional specificity in cancer cells remains unclear. It may simply be that inappropriate expression of FACT in normal cell types is sufficient to collaborate with other oncogenic transcription factors to drive a gene program that favors malignant transformation and transcription.
Our results demonstrate that FACT can enhance MYCN transcription and protein stability in neuroblastoma cells, even those with multiple copies of MYCN and an already high MYCN expression. Although MYCN amplification is a common feature of human neuroblastoma, recent studies have indicated that mechanisms in addition to gene amplification are required to maintain the very high MYCN protein concentrations necessary for the fully malignant phenotype (34) (35) (36) (37) . Collectively, these findings are consistent with observations made in tumorigenic murine Myc models showing that different thresholds of MYC expression result in different components of the malignant phenotype, and suggest that MYCN expression and protein stability are important treatment targets (38) .
For neuroblastoma patients with advanced disease, prognosis is still poor (1, 2). Many of these patients' tumors are characterized by MYCN amplification or overactivation of MYC target genes (6) . We show here that CBL0137 was highly effective against established primary tumors and pulmonary metastases in TH-MYCN +/+ mice and that CBL0137 treatment was accompanied by marked MYCN depletion in tumors after only a single intravenous dose, suggesting that targeting FACT may be an important strategy to decrease MYCN expression and overcome primary and metastatic disease (37, (39) (40) (41) . This treatment approach is particularly promising because the expression of MYCN and FACT is markedly higher in malignant compared with normal tissues (10, 11, 15) . Accordingly, our data showed that CBL0137 inhibition of FACT and MYCN was associated with extensive cytotoxicity in advanced TH-MYCN +/+ tumors but exhibited minimal toxicity, consistent with findings in other animal models of cancer (12) . Moreover, the previously described inhibitory activity of CBL0137 against nuclear factor kB (NFkB)transcriptional targeting and activation of p53 by casein kinase-dependent Ser 32 phosphorylation (12) makes CBL0137 a potential multimodal cancer therapeutic Fig. 7 . CBL0137 prevents DNA damage repair after genotoxic chemotherapy. (A) BE(2)C cells were treated for 24 hours with or without the following chemotherapeutics: 2 mM cisplatin (left) or 5 mM etoposide (right). Chemotherapeutics were subsequently removed, and medium was supplemented with or without 100 nM CBL0137 for 22 hours (refer to schematic above gel for the administration schedule). The repair of chemotherapy-induced DNA double-strand breaks (DSBs) in the presence or absence of CBL0137 was determined using pulsed-field gel electrophoresis. Data displayed are representative of two independent biological replicates. Dashed white lines indicate areas where gel was cropped for presentation. (B) BE(2)C cells were treated with or without 5 mM etoposide for 5 hours. Etoposide was subsequently removed, and medium was supplemented with or without 200 nM CBL0137 for 3 hours (refer to schematic above the images for the administration schedule). Cells were then fixed and processed for immunofluorescence with anti-gH2AX (red) and anti-53BP1 (green), as well as 4′,6-diamidino-2-phenylindole (DAPI) DNA stain (blue). for a variety of malignancies characterized by defects within these pathways.
FACT has been shown to promote DNA damage repair in the face of DNA-damaging chemotherapy (22) , suggesting that it may act as a chemoresistance factor. Here, we showed that CBL0137 was particularly effective as a combination therapy with chemotherapeutic agents. In addition, combining CBL0137 with chemotherapy regimens currently used after relapse potentiated its activity, highlighting a potential therapeutic strategy for high-risk neuroblastoma patients. Although our data and those of others have shown that CBL0137 alone is not genotoxic (12) , inhibition of FACT created a synthetic lethal environment in the presence of cisplatin and etoposide but not vincristine. Moreover, combinations of CBL0137 with DNA-damaging agents such as cisplatin, cyclophosphamide, and etoposide were better tolerated in our mouse models than the nongenotoxic microtubule inhibitor vincristine, suggesting that the most effective role for CBL0137 in anticancer therapy will be coadministration with primary DNA-damaging agents. We also observed that p53 status was not a determinant of CBL0137 combination therapy sensitivity, consistent with previous findings for CBL0137 as a single agent in adult cancer types (12) . Considering that genotoxic chemotherapy is associated with marked nonspecific toxicity in patients, targeting FACT with the nongenotoxic CBL0137 promises to enhance cancer cell specificity of these agents, which are the current mainstay of neuroblastoma therapy.
Future studies will need to address some of the limitations of this study. First, it will be necessary to unveil the specific mechanism by which FACT modifies MYCN expression at both the transcriptional and posttranslational level. Second, we still lack in-depth understanding of the mechanism and consequences of CBL0137-induced changes in chromatin, in particular how this relates to inhibition of FACTdependent transcriptional programs and to specific DNA repair pathways that are affected. Detailed analyses of CBL0137 effects on DNA repair pathways such as homologous repair and nonhomologous end joining will be required. Third, the mechanism by which CBL0137 accumulates at high concentration in neuroblastoma tumors and whether this occurs in other cancer types are unknown. In particular, mechanisms of CBL0137 uptake, metabolism, and efflux will need to be elucidated. Finally, it remains to be explored whether CBL0137 can be used as a therapy for other cancers and whether MYC deregulation can serve as a biomarker for CBL0137 sensitivity. With these additional studies, CBL0137 or newer FACT inhibitors may serve as a therapy for neuroblastoma and potentially other MYC-driven cancers.
MATERIALS AND METHODS
Detailed methods are available in the Supplementary Materials.
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